A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 7, 1998, Pages 2435-2440

  Latronico, A C ^c   Abell, A N ^a   Arnhold, I J P ^c   Liu, X ^a   Lins, T S S ^b   Brito, V N ^c   Billerbeck, A E ^c   Segaloff, D L ^a   Mendonca, B B ^c  

^a UNIVERSITY OF IOWA   (United States)

^b INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; FOLLITROPIN; GONADORELIN; GONADOTROPIN; KETOCONAZOLE; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; MEDROXYPROGESTERONE ACETATE; TESTOSTERONE;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CASE REPORT; CHILD; CONFORMATIONAL TRANSITION; EXON; FOLLITROPIN BLOOD LEVEL; GENE ACTIVATION; HETEROZYGOSITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEYDIG CELL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; POINT MUTATION; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROVOCATION TEST; SEQUENCE ANALYSIS; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL;

EID: 0031728024     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.7.2435     Document Type: Article

References (31)

1. Rosenthal SM, Grumbach M, Kaplan SL. 1983 Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab. 57:571-579.
2. Shenker A, Laue L, Kosugi S, Merendino Jr JJ, Minegishi T, Cutler Jr GB. 1993 A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 365:652-654.
3. Kremer H, Edwin M, Otten BJ, et al. 1993 Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. Hum Mol Genet. 2:1779-1783.
4. Laue L, Chan WY, Hsueh AJW, et al. 1995 Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci USA. 92:1906-1910.
5. Yano K, Saji M, Hidaka A, et al. 1995 A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J Clin Endocrinol Metab. 80:1162-1168.
6. Kosugi S, Dop CV, Geffner ME, et al. 1995 Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet. 4:183-188.
7. Latronico AC, Anasti J, Amhold IJP, et al. 1995 A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab. 80:2490-2494.
8. Kraaij R, Post M, Kremer H, et al. 1995 A missense mutation in the second transmembrane segment of the luteinizing hormone receptor causes familial male-limited precocious puberty. J Clin Endocrinol Metab. 80:3168-3172.
9. Minegishi T, Nakamura K, Takamura Y, et al. 1990 Cloning and sequencing of human/hCG receptor cDNA. Biochem Biophys Res Commun. 172:1049-1054.
10. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. 1989 Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:51-59.
11. Chen C, Okayama H. 1987 High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 7:2745-2752.
12. De Lean A, Munson PJ, Rodbard D. 1978 Simultaneous analysis of families of sigmoidal curves: application to biossay, radioligand assay and physiological dose-response curves. Am J Physiol 235:E97-E102.
13. Munson PJ, Rodbard D. 1980 LIGAND: a versatile computerized approach for characterization of ligand-binding system. Anal Biochem. 107:220-239.
14. 1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization. J Biol Chem. 271:7956-7964.
15. Whaley BS, Yuan N, Birnbaumer L, Clark RB, Barber R. 1994 Differential expression of the β-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol Pharmacol. 45:481-489.
16. Zhu X, Gilbert S, Birnbaumer M, Bimbaumer L. 1994 Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density. Mol Pharmacol. 46:460-469.
17. Shenker A. 1998 In: Spiegel AM, ed. G protein and disease. Totowa, NJ: Human Press, (in press).
18. 111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J Biol Chem. 272:1822-1826.
19. 1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem. 271:28318-28323.
20. Epstein FH. 1997 The thyrotropin receptor in thyroid diseases. N Engl J Med. 337:1675-1681.
21. Baldwin JM. 1993 The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1693-1703.
22. Baldwin JM, Schertler GFX, Unger VM. 1997 An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol. 272:144-164.
23. Lin Z, Shenker A, Pearlstein R. 1997 A model of the lutropin/choriogonadotropin receptor: insights into the structure and functional aspects of constitutively activating mutations. Protein Eng. 10:5015-5010.
24. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. 1996 Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science. 274:768-770.
25. Hargrave P, McDowell JH. 1992 Rhodopsin and photorransduction: a model system for G protein-linked receptors. FASEB J. 6:2323-2331.
26. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR. 1996 Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature. 383:347-350.
27. Abell AN, Segaloff DL 1997. Evidence for the direct involvement of transmembrane region six of the lutropin/choriogonadotropin receptor in activating Gs. J Biol Chem. 272:14586-14591.
28. Javitch JA, Fu D, Liapakis G, Chen J. 1997 Constitutive activation of the β2-adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem. 272:18546-18549.
29. Bourne HR. 1997. How receptors talk to trimeric G proteins. Curr Opin Cell Biol. 9:134-142.
30. Bond RA, Leff P, Johnson D, Milano CA, et al. 1995 Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoreceptor. Nature. 374:72-76.
31. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. 1993 A mutation-induced activated state of the β2-adrenergic receptor: extending the ternary complex model. J Biol Chem. 268:4625-4636.